- Rheumatologie-App Injektionstechnik
- Neue Studien
- Kongress Highlights
- EULAR 2020
- EULAR 2019
- EULAR 2018
- EULAR 2017
- EULAR 2016
- EULAR 2015
- EULAR 2014
- ACR 2020
- ACR 2019
- ACR 2018
- ACR 2017
- ACR 2015
- ACR 2014
- Rheuma Top 2019
- Rheuma Top 2018
- Rheuma Top 2017
- Rheuma Top 2015
- Rheuma Top 2014
- Bilddatenbank
- RheumaTool
- SlideSet RA
- SlideSetSpA
- SonoTool
- FOCUS «Der Fuss»
- FOCUS «Die Hand»
- FOCUS «Kinderrheuma»
- EisenPaket
- LupusPaket
- OsteoPaket
- Publikationen
- Literaturservice
- Richtlinien
- Schmerzpaket
- Immunotalk
ACR 2020 | Daily Highlights
Vom 5. bis 9. November 2020 fassten unsere Schweizer Rheumaexperten für Sie die praxisrelevantesten Abstracts des ACR-Kongresses zusammen und kommentierten diese.
Rheumatoide Arthritis (RA)
Prof. Dr. Axel Finckh
Genf
Psoriatic Arthritis
Prof. Dr. Andrea Rubbert-Roth
St. Gallen
Abstracts
- 06.11.2020 | 0508 |
MTX optimization versus adding adalimumab - 06.11.2020 | 0333 |
Real life effectiveness of secukinumab versus TNF inhibitors - 06.11.2020 | 0326 |
Flares: how do they impact patients' daily life? - 08.11.2020 | 2856 |
Safety profile of upadacitinib - 09.11.2020 | L03 |
Targeting TYK2: Will there be a «new kid on the ground» for psoriatic arthritis therapy? - 09.11.2020 | 1850 |
Different clinical phenotypes of PsA – the same disease?
Spondyloarthritis
Prof. Dr. Diego Kyburz
Basel
Abstracts
- 08.11.2020 | 1444 |
Treat-to-Target - 09.11.2020 | 2023 |
Upadacitinib - 09.11.2020 | 2013 |
Lifetime risk in relatives - 09.11.2020 | 2029 |
Therapeutic drug monitoring under infliximab - 09.11.2020 | 2028 |
Etanercept: withdrawal and retreatment - 09.11.2020 | 2030 |
COX-2 inhibitors and radiographic progression
Vasculitis
Prof. Dr. Peter Villiger
Bern
Connective Tissue Diseases
Prof. Dr. Ulrich Walker
Basel
Additional Topics
Dr. Thomas Langenegger
Zug
Abstracts
Mit freundlicher Unterstützung von:
Eli Lilly (Suisse) SA
1214 Vernier/Geneva
Roche Pharma (Schweiz) AG
4153 Reinach
